MiBolsilloColombia on MSN
CVS agrees to pay $37.8 million in record insulin pen fraud case
A record $37.8 million settlement closes a decade-long case alleging that CVS overbilled government health programs by ...
CVS Health will pay $37.76 million to settle allegations it dispensed too many insulin pens to patients, and then obtained ...
EL SEGUNDO, Calif. — Gov. Gavin Newsom announced Thursday that CalRx biosimilar insulin glargine pens will be available to consumers in California beginning Jan. 1, 2026. The launch comes amid the ...
The Go-Pen insulin pen. [Image courtesy of the company] Go-Pen announced today on social media that it received CE mark approval for its user-fillable insulin pen. The Denmark-based company said on ...
SACRAMENTO – As the first and only state contracting for its own affordable insulin, Governor Gavin Newsom announced Oct. 16 that CalRx® biosimilar insulin glargine pens will be available to consumers ...
The state’s CalRx Insulin Glargine will be available to consumers for a suggested retail price of $55 or less per five-pack of pens beginning Jan. 1, 2026. The insulin glargine pen agreement with ...
Share on Pinterest Experts say California’s new affordable insulin program is a breakthrough for people with diabetes. Getty Images California has launched a program to manufacture and sell lower-cost ...
Litigation over Medtronic Plc’s alleged scheme to avoid $100 million in deal payments by sabotaging sales of a reusable insulin pen ended with an anticlimax Monday. The order formally dismissing the ...
California’s CalRx insulin pens will launch Jan. 1 at $11 each, or $55 for a five-pack The state has invested $100 million to lower insulin costs The effort could save patients $2,000 to $4,000 a year ...
Annalisa (Nalis) Merelli is a contributing writer at STAT focused on boys’ and men’s health. Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign ...
The integration of eGDR into clinical models enhanced predictive accuracy of future CVD among patients with cardiovascular-kidney-metabolic syndrome stages 0 to 3. Individuals with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback